Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources

被引:57
作者
Chen, L
Pulsipher, M
Chen, DS
Sieff, C
Elias, A
Fine, HA
Kufe, DW
机构
[1] HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115
[2] HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT HEMATOL & ONCOL,BOSTON,MA 02115
关键词
adenovirus; bone marrow; breast cancer; thymidine kinase; gene therapy;
D O I
10.1172/JCI119072
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Tumor contamination of bone marrow (BM) and peripheral blood (PB) may affect the outcome of patients receiving high dose chemotherapy with autologous transplantation of hematopoietic stem cell products. In this report, we demonstrate that replication defective adenoviral vectors containing the cytomegalovirus (CMV) or DF3/MUC1 carcinoma-selective promoter can be used to selectively transduce contaminating carcinoma cells, Adenoviral-mediated reporter gene expression in breast cancer cells was five orders of magnitude higher than that found in BM, PB, and CD34(+) cells. Our results demonstrate that CD34(+) cells have low to undetectable levels of integrins responsible for adenoviral internalization. We show that adenoviral-mediated transduction of a reporter gene can detect one breast cancer cell in 5 x 10(5) BM or PB cells with a vector containing the DF3/MUC1 promoter. We also show that transduction of the HSV-tk gene for selective killing by ganciclovir can be exploited for purging cancer cells from hematopoietic stem cell populations. The selective expression of TK followed by ganciclovir treatment resulted in the elimination of 6-logs of contaminating cancer cells. By contrast, there was little effect on CFU-GM and BFU-E formulation or on long term culture initiating cells. These results indicate that adenoviral vectors with a tumor-selective promoter provide a highly efficient and effective approach for the detection and purging of carcinoma cells in hematopoietic stem cell preparations.
引用
收藏
页码:2539 / 2548
页数:10
相关论文
共 47 条
[31]   HIGH-DOSE COMBINATION ALKYLATING-AGENTS WITH BONE-MARROW SUPPORT AS INITIAL TREATMENT FOR METASTATIC BREAST-CANCER [J].
PETERS, WP ;
SHPALL, EJ ;
JONES, RB ;
OLSEN, GA ;
BAST, RC ;
GOCKERMAN, JP ;
MOORE, JO .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) :1368-1376
[32]   HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT AS CONSOLIDATION AFTER STANDARD-DOSE ADJUVANT THERAPY FOR HIGH-RISK PRIMARY BREAST-CANCER [J].
PETERS, WP ;
ROSS, M ;
VREDENBURGH, JJ ;
MEISENBERG, B ;
MARKS, LB ;
WINER, E ;
KURTZBERG, J ;
BAST, RC ;
JONES, R ;
SHPALL, E ;
WU, K ;
ROSNER, G ;
GILBERT, C ;
MATHIAS, B ;
CONIGLIO, D ;
PETROS, W ;
HENDERSON, IC ;
NORTON, L ;
WEISS, RB ;
BUDMAN, D ;
HURD, D .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) :1132-1143
[33]  
ROSS AA, 1993, BLOOD, V82, P2605
[34]  
Seth P, 1996, CANCER RES, V56, P1346
[35]  
SHPALL EJ, 1991, BONE MARROW TRANSPL, V7, P145
[36]   4-HYDROPEROXYCYCLOPHOSPHAMIDE PURGING OF BREAST-CANCER FROM THE MONONUCLEAR CELL FRACTION OF BONE-MARROW IN PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS MARROW SUPPORT - A PHASE-I TRIAL [J].
SHPALL, EJ ;
JONES, RB ;
BAST, RC ;
ROSNER, GL ;
VANDERMARK, R ;
ROSS, M ;
AFFRONTI, ML ;
JOHNSTON, C ;
EGGLESTON, S ;
TEPPERBURG, M ;
CONIGLIO, D ;
PETERS, WP .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (01) :85-93
[37]  
SIMPSON SJ, 1995, EXP HEMATOL, V23, P1062
[38]  
STEEL RGD, 1960, PRINCIPLES PROCEDURE, P1
[39]   FUNCTIONAL-CHARACTERIZATION OF INDIVIDUAL HUMAN HEMATOPOIETIC STEM-CELLS CULTURED AT LIMITING DILUTION ON SUPPORTIVE MARROW STROMAL LAYERS [J].
SUTHERLAND, HJ ;
LANSDORP, PM ;
HENKELMAN, DH ;
EAVES, AC ;
EAVES, CJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (09) :3584-3588
[40]  
TASWELL C, 1981, J IMMUNOL, V126, P1614